RxDoctor Payments Data

William Gordon

Psychiatric/Mental Health · Goodyear, AZNPI 1275780009

Payments from drug & device makers

$2,568in general payments, 2019–2025

Across 51 payments — averaging $50.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$577
  • AbbVie$499
  • Teva Pharmaceuticals USA, Inc.$426
  • Neurocrine Biosciences, Inc.$253
  • Otsuka America Pharmaceutical, Inc.$198
  • Johnson & Johnson$167
  • plus $447 from 5 others

What the payments were for

  • Food & beverage$2,568100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,568 in reported general payments places this provider in the 85th percentile of 1,230 psychiatric/mental health providers in Arizona.

See all psychiatric/mental health providers in Arizona

Medicare billing

Part B allowed, 2024
$4,334
Medicare patients
18
Services billed
58

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate21$155,189
Invega SustennaPaliperidone Palmitate19$67,547
AristadaAripiprazole Lauroxil26$66,694
Lurasidone Hcl82$10,762
Clozapine81$6,903
Fluphenazine Hcl32$1,964
Propranolol Hcl127$1,563
Benztropine Mesylate90$1,432
Divalproex Sodium ErDivalproex Sodium26$1,415
Trazodone Hcl131$1,377
Paliperidone ErPaliperidone17$1,325
Carbamazepine ErCarbamazepine21$1,216
Olanzapine55$1,141
Hydroxyzine Hcl56$1,117
Oxcarbazepine13$1,042

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$253$155,18921 claims
Johnson & JohnsonInvega Sustenna$167$67,54719 claims
Alkermes, Inc.Aristada$577$66,69426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,230 psychiatric/mental health providers in Arizona.

Other psychiatric/mental health in Goodyear

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →